BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28039263)

  • 1. Variants in
    Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
    Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
    [No Abstract]   [Full Text] [Related]  

  • 2. Further Investigation of the Role of
    Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
    Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
    Zhang X; Trendowski MR; Wilkinson E; Shahbazi M; Dinh PC; Shuey MM; ; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Huddart R; Martin NE; Sanchez VA; Frisina RD; Einhorn LH; Cox NJ; Travis LB; Dolan ME
    Cancer Med; 2022 Jul; 11(14):2801-2816. PubMed ID: 35322580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.
    Dolan ME; El Charif O; Wheeler HE; Gamazon ER; Ardeshir-Rouhani-Fard S; Monahan P; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kim J; Fossa SD; Hertz DL; Mushiroda T; Kubo M; Einhorn LH; Cox NJ; Travis LB;
    Clin Cancer Res; 2017 Oct; 23(19):5757-5768. PubMed ID: 28611204
    [No Abstract]   [Full Text] [Related]  

  • 5. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
    Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
    J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
    Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
    Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
    Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
    JAMA Oncol; 2017 Nov; 3(11):1558-1562. PubMed ID: 28448657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
    Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
    J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
    El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
    Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
    Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
    Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.
    Trendowski MR; El Charif O; Dinh PC; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Feb; 25(4):1147-1155. PubMed ID: 30305294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating IL-17 reduces the risk of cisplatin-induced hearing loss in children: a bidirectional two-sample Mendelian randomization study.
    Xu Y; Huang C; Liu J; Xu Y; Yang H
    Sci Rep; 2023 Nov; 13(1):18957. PubMed ID: 37919361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic background of cisplatin induced ototoxicity].
    Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
    Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy.
    Noszek L; Budai B; Prekopp P; Széchenyi R; Szőnyi M; Talpai S; Nagyiványi K; Bíró K; Géczi L
    Laryngoscope; 2017 Aug; 127(8):E277-E282. PubMed ID: 27666741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
    Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
    Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.